Compare
Disc Medicine, Inc. vs MannKind Corp vs uniQure N.V. vs Maravai Lifesciences Holdings, Inc.
| Latest fiscal year | Disc Medicine, Inc. IRON | MannKind Corp MNKD | uniQure N.V. QURE | Maravai Lifesciences Holdings, Inc. MRVI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $348.97M | $16.10M | $185.74M |
| Revenue growth (YoY) | n/a | +22.2% | -40.6% | -28.3% |
| Gross margin | n/a | 92.3% (computed) | 89.5% (computed) | 18.3% |
| Operating margin | n/a | 11.1% | n/m | -115.9% |
| Net margin | n/a | 1.7% | n/m | -70.4% |
| Net income | -$212.18M | $5.86M | -$198.97M | -$130.77M |
| EPS (Diluted) | -$6.01 | $0.02 | -$3.46 | -$0.90 |
| Operating cash flow | -$180.39M | $18.25M | -$177.96M | -$57.57M |
| Free cash flow | -$181.33M | $13.69M | -$178.40M | -$70.72M |
| Cash & equivalents | $91.14M | $74.88M | $80.24M | $216.89M |
| Total assets | $806.88M | $792.18M | $824.91M | $770.58M |
| Total liabilities | $67.05M | $843.20M | $626.01M | $397.87M |
| Shareholders' equity | $739.83M | -$51.02M | $198.90M | $212.38M |
| Return on year-end equity | -28.7% | n/a | -100.0% | -61.6% |
| Shares outstanding | 37.89M | 307.83M | 62.34M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Disc Medicine, Inc. | MannKind Corp | uniQure N.V. | Maravai Lifesciences Holdings, Inc. |
|---|---|---|---|---|
| Latest | n/a | $348.97M Ended 2025-12-31 | $16.10M Ended 2025-12-31 | $185.74M Ended 2025-12-31 |
| 1 year earlier | n/a | $285.50M Ended 2024-12-31 | $27.12M Ended 2024-12-31 | $259.19M Ended 2024-12-31 |
| 2 years earlier | n/a | $198.96M Ended 2023-12-31 | $15.84M Ended 2023-12-31 | $288.94M Ended 2023-12-31 |
| 3 years earlier | n/a | $99.77M Ended 2022-12-31 | $106.48M Ended 2022-12-31 | $883.00M Ended 2022-12-31 |
| 4 years earlier | n/a | $75.44M Ended 2021-12-31 | $524.00M Ended 2021-12-31 | $799.24M Ended 2021-12-31 |